Global narcolepsy therapeutics market is expected to reach over USD 1,996.06 million by 2020, according to a new study by Grand View Research Inc. Growing prevalence of the target disease is anticipated to be the key driver for narcolepsy therapeutics industry growth. According to the estimates by the Narcolepsy Network, approximately 1 in 2,000 people in the U.S. suffer from the target disease. Steep increase in the incidence rates of the disease was observed in several countries of Europe after H1N1 vaccination program in 2009, which led to rise in awareness about this rare disorder. Furthermore, patient awareness programs conducted by various organizations, such as Narcolepsy Network Inc., European Narcolepsy Network, Wake Up Narcolepsy, American Sleep Association, Narcolepsy Canada, and Narcolepsy UK accelerate the number of diagnoses and treatment, and drive industry growth. Presence of favorable reimbursement policies for FDA-approved prescription medicines such as Xyrem further boosts the market growth. Further key findings from the study suggest: Narcolepsy with cataplexy segment is estimated to have over 55% market share in 2014 owing to diagnosis of cataplexy as the confirming symptom in the patients. It is estimated that nearly 75% of patients are expected to have symptoms of cataplexy over a period of time. Narcolepsy without cataplexy is estimated to be the fastest growing segment of market with a CAGR of over 12% during the forecast period. Key factor attributing for the market growth includes rising number of awareness campaigns conducted by various narcolepsy networks, which are expected to increase the number of diagnoses and treatment over the forecast period. Sodium Oxybate dominated the overall industry in 2014, with market share of over 78%. Xyrem is the only FDA-approved drug specially indicated for usage in cataplexy and EDS associated with narcolepsy from this category. Presence of favorable reimbursement policies, high prices associated with this drug, and the rising awareness levels pertaining to the disease are few factors responsible for the large share of this segment. CNS stimulants are considered to be the first line of treatment for various sleep disorders such as ADHD, obstructive sleep apnea, and work shift disorder. However, they are estimated to lose market share over the forecast period owing to patent expiration of key drugs in this category such as Provigil and Nuvigil. Europe is estimated to be the largest region of the industry. It dominated the market in terms of revenue with USD 375.23 million in 2014, owing to better patient and practitioner awareness levels about this rare disorder and presence of favorable government initiatives pertaining to its research and development. Asia Pacific is expected to witness significant growth with a CAGR of around 13% over the forecast period owing to emerging economies in this region, rising investments in pharmaceutical and biotechnology sector, supportive government initiatives, and rapidly growing healthcare industry. Moreover, prevalence rates in Japan are reported to be the highest as compared to the other major countries of the world. Major players operating in the market include Teva Pharmaceutical Industries Ltd., Addrenex Pharmaceuticals, Jazz Pharmaceuticals Plc, Arena Pharmaceuticals, Ligand Pharmaceuticals, Graymark Healthcare Inc., Shire Plc, and BIOPROJET Industry participants are constantly engaged in spreading awareness about this rare disease amongst the physicians and the patients. Strategic alliances and licensing deals amongst the major players of the industry further drive industry growth.
Table of Content Chapter 1 Methodology and Scope 1.1 Research Methodology 1.2 Research Scope & Assumptions 1.3 List of Data Sources Chapter 2 Executive Summary Chapter 3 Narcolepsy Therapeutics Industry Outlook 3.1 Market Segmentation 3.2 Market Size and Growth Prospects 3.2.1 Market driver analysis 22.214.171.124 Increasing global prevalence of narcolepsy 126.96.36.199 Awareness programs 188.8.131.52 Presence of reimbursement policies. 3.2.2 Market restraint analysis 3.3.3 Narcolepsy therapeutics market - Key market restraint analysis 184.108.40.206 Side-effects and risks 220.127.116.11 Misdiagnosis and delayed diagnosis 3.3 Key Opportunities Prioritized 3.4 Narcolepsy Therapeutics - PESTEL Analysis 3.5 Narcolepsy Therapeutics: Untapped opportunity Chapter 4 Narcolepsy Therapeutics Type Outlook 4.1 Narcolepsy Therapeutics Market Share by Type, 2014 & 2020 4.2 Narcolepsy with cataplexy 4.2.1 Narcolepsy with cataplexy market, 2012 - 2020 (USD Million) 4.3 Narcolepsy without cataplexy 4.3.1 Narcolepsy without cataplexy market, 2012 - 2020 (USD Million) 4.4 Secondary narcolepsy 4.4.1 Secondary narcolepsy market, 2012 - 2020 (USD Million) Chapter 5 Narcolepsy Therapeutics Product Outlook 5.1 Narcolepsy Therapeutics Market Share by Product, 2014 & 2020 5.2 Central Nervous system stimulants 5.2.1 Central nervous system stimulants market, 2012 - 2020 (USD Million) 5.3 Sodium oxybate 5.3.1 Sodium oxybate market, 2012 - 2020 (USD Million) 5.4 Selective Serotonin Reuptake Inhibitor (SSRI) 5.4.1 Selective Serotonin Reuptake Inhibitor (SSRI) market, 2012 - 2020 (USD Million) 5.5 Tricyclic antidepressants 5.5.1 Tricyclic antidepressants market, 2012 - 2020 (USD Million) 5.6 Other narcolepsy drugs 5.6.1 Other narcolepsy drugs market, 2012 - 2020 (USD Million) Chapter 6 Narcolepsy Therapeutics Regional Outlook 6.1 Narcolepsy Therapeutics Market Share by Region, 2014 & 2020 6.2 North America 6.2.1 North America Narcolepsy Therapeutics Market, 2012-2020 (USD Million) 6.3 Europe 6.3.1 Europe Narcolepsy Therapeutics Market, 2012-2020 (USD Million) 6.4 Asia Pacific Narcolepsy Therapeutics Market 6.4.1 Asia Pacific Narcolepsy Therapeutics Market, 2012-2020 (USD Million) 6.5 RoW Narcolepsy Therapeutics Market 6.5.1 RoW Narcolepsy Therapeutics Market, 2012-2020 (USD Million) Chapter 7 Competitive Landscape 7.1 Addrenex Pharmaceuticals, Inc. 7.1.1 Company Overview 7.1.2 Financial Performance 7.1.3 Product Benchmarking 7.1.4 Strategic Initiatives 7.2 Teva Pharmaceutical Industries Ltd. 7.2.1 Company Overview 7.2.2 Financial Performance 7.2.3 Product Benchmarking 7.2.4 Strategic Initiatives 7.3 Jazz Pharmaceuticals, Inc. 7.3.1 Company Overview 7.3.2 Financial Performance 7.3.3 Product Benchmarking 7.3.4 Strategic Initiatives 7.4 Graymark Healthcare, Inc. 7.4.1 Company Overview 7.4.2 Financial Performance 7.4.3 Product Benchmarking 7.4.4 Strategic Initiatives 7.5 Arena Pharmaceuticals, Inc. 7.5.1 Company Overview 7.5.2 Financial Performance 7.5.3 Product Benchmarking 7.5.4 Strategic Initiatives 7.6 BIOPROJET 7.6.1 Company Overview 7.6.2 Financial Performance 7.6.3 Product Benchmarking 7.6.4 Strategic Initiatives 7.7 Shire Pharmaceuticals 7.7.1 Company Overview 7.7.2 Financial Performance 7.7.3 Products Benchmarking 7.7.4 Strategic Initiatives 7.8 Ligand Pharmaceuticals 7.8.1 Company Overview 7.8.2 Financial Performance 7.8.3 Products Benchmarking 7.8.4 Strategic Initiatives
List of Tables TABLE 1 Narcolepsy Therapeutics Market - Industry Summary & Critical Success Factors (CSFs) TABLE 2 Narcolepsy Therapeutics market, by region, 2012 - 2020 (USD Million) TABLE 3 Narcolepsy Therapeutics market, by type, 2012 - 2020 (USD Million) TABLE 4 Narcolepsy Therapeutics market, by treatment, 2012 - 2020 (USD Million) TABLE 5 Narcolepsy therapeutics market - Key market driver analysis TABLE 6 Central nervous system stimulants market: Drug overview TABLE 7 Sodium oxybate market: Drug overview TABLE 8 Serotonin Reuptake Inhibitor (SSRI) market: Drug overview TABLE 9 Tricyclic antidepressant market: Drug overview TABLE 10 Other narcolepsy drugs market: drug overview TABLE 11 North America narcolepsy therapeutics market, by type, 2012 - 2020 (USD Million) TABLE 12 North America narcolepsy therapeutics market, by treatment, 2012 - 2020 (USD Million) TABLE 13 Europe narcolepsy therapeutics market, by type, 2012 - 2020 (USD Million) TABLE 14 Europe narcolepsy therapeutics market, by treatment, 2012 - 2020 (USD Million) TABLE 15 Asia Pacific narcolepsy therapeutics market, by type, 2012 - 2020 (USD Million) TABLE 16 Asia Pacific narcolepsy therapeutics market, by treatment, 2012 - 2020 (USD Million) TABLE 17 RoW narcolepsy therapeutics market, by type, 2012 - 2020 (USD Million) TABLE 18 RoW narcolepsy therapeutics market, by treatment, 2012 - 2020 (USD Million)
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.